Entera Bio Ltd., a clinical-stage company developing oral peptide therapies, announced that CEO Miranda Toledano will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The event will be held in Boston and streamed online, providing insights into Entera's innovative oral treatments for osteoporosis and other conditions. This participation highlights Entera's progress and commitment to advancing its pipeline, including its lead product EB613, an oral osteoporosis treatment currently in Phase 2 trials.
AlphaPepe's crypto presale has raised over $3.1 million with more than 12,600 holders, showing strong retail demand before its public exchange debut. The project features a live AI-powered DEX called AlphaSwap and is led by an ex-Shibarium developer,...
The 2026 iCAUR International User Summit in Wuhu, China, introduced the new iCAUR V25, expanding the V-Series lineup alongside the V23 and V27. The event highlighted the brand's Future Classic Design philosophy, vehicle customization, and user co-cre...
HUTCHMED has finalized an exclusive license agreement with GSK granting GSK rights to develop and commercialize HMPL-A830, a novel KRAS-EGFR antibody conjugate therapy, outside China, Hong Kong, Macau, and Taiwan. This therapy targets cancers with KR...
Hotel101 Global Holdings Corp has signed binding agreements to enter Egypt with a joint venture to develop Hotel101-Cairo West, a 750-room hotel near the Giza Pyramids and Grand Egyptian Museum. This marks Hotel101's first project in Africa and is pa...
Injective and South Korean digital asset custodian BDACS signed a memorandum of understanding to explore using KRW1, a token backed one-to-one by Korean won reserves, for settling tokenized assets directly in won on Injective's blockchain. This initi...
